CPI-613 may be used to treat clear cell sarcoma, pancreatic, biliary tract cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Several ongoing trials demonstrate that CPI-613 (devimistat) is a potential treatment for pancreatic cancer, clear cell sarcoma, and biliary tract cancer. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login